Financials
- Market Capitalization 2.52 B
- Employee 1 371
- Founded 2010
- CEO Emil Kakkis
- Website www.ultragenyx.com
- Headquarter Delaware, United States
- FIGI BBG001RWPDW6
- Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-3.95
Rapporto prezzo/fatturato
3.37
Related tickers
| # | Nome | Prezzo | 24h % | 7d % | 1M % | 1Y % | Valore di Mercato | Ultimi 7 Giorni | |
|---|---|---|---|---|---|---|---|---|---|
| 1792 | ATAI AtaiBeckley Inc. - Common Stock | 7.30 USD | -0.68% | -1.08% | +1.81% | +84.81% | 2.71 B USD | ||
| 1824 | VRDN Viridian Therapeutics, Inc. - Common Stock | 23.09 USD | -3.31% | -4.94% | +18.05% | +2.85% | 2.62 B USD | ||
| 1850 | PGEN Precigen, Inc. - Common Stock | 6.94 USD | -3.48% | -3.61% | +24.82% | +53.54% | 2.48 B USD | ||
| 1852 | BCRX BioCryst Pharmaceuticals, Inc. - Common Stock | 9.82 USD | -0.51% | +2.83% | +1.66% | +16.08% | 2.51 B USD |